Abryl Laboratories announced the approval of its Abbreviated New Drug Application (ANDA) for Regadenoson Injection in pre-filled syringes. This approval marks a significant milestone for the company, as the product will be manufactured at its state-of-the-art facility, ensuring high quality and compliance with international standards.
Abryl Laboratories is a state-of-the-art manufacturing facility for sterile liquid and lyophilized products, and pre-filled syringes. Founded in 2016, Abryl has a single mission to provide top-notch quality products for the world. With a capacity to manufacture over 60 million liquid vials and ampoules,
